
    
      The primary study objective is to assess the safety of a bivalent vaccine of two new 6:2
      influenza virus reassortants in healthy adults prior to the release of the trivalent vaccine
      (FluMist) containing them. Safety will be demonstrated by similar fever rates (oral
      temperature ≥101°F Days 0-7) in vaccine and placebo recipients.
    
  